Method for predicting the response to HER2-directed therapy

摘要

This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.

主权项

1. A method for identifying a breast tumor that has previously been treated with at least one chemotherapeutic as likely to respond to trastuzumab, comprising:
measuring in a sample obtained from the breast tumor:
a) expression of epidermal growth factor receptor (EGFR) polypeptide; andb) phosphorylation of extracellular signal-regulated kinase (ERK) polypeptide, wherein phosphorylation of ERK polypeptide is measured using an antibody specific for an epitope comprising a phosphorylated threonine at position 202 of SEQ ID NO: 3, a phosphorylated tyrosine at position 204 of SEQ ID NO: 3, or a combination thereof; identifying the breast tumor as a breast tumor likely to respond to trastuzumab, if the breast tumor is positive for EGFR polypeptide expression and negative for phosphorylation of ERK polypeptide; and administering trastuzumab to the subject from which the breast tumor sample was obtained if the breast tumor is positive for EGFR polypeptide expression and negative for phosphorylation of ERK polypeptide.